NP Life Sciences Health Industry Group Inc. (NPLS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
4125 BLACKHAWK PLAZA CIRCLE DANVILLE, CA 94506 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 82 - Educational Services (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 122 | 28 | 119 | 243 | |||
| Cash and cash equivalents | 122 | 28 | 119 | 243 | |||
| Prepaid expense | 6 | 10 | |||||
| Total current assets: | 128 | 38 | 119 | 243 | |||
| Noncurrent Assets | |||||||
| Intangible assets, net (including goodwill) | 7 | ||||||
| Intangible assets, net (excluding goodwill) | 7 | ||||||
| Total noncurrent assets: | 7 | ||||||
| TOTAL ASSETS: | 128 | 38 | 119 | 250 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 9 | 0 | 15 | 15 | |||
| Accounts payable | 6 | 1 | |||||
| Accrued liabilities | 3 | 0 | 15 | 14 | |||
| Deferred revenue | 100 | ||||||
| Debt | |||||||
| Total current liabilities: | 108 | 0 | 15 | 15 | |||
| Noncurrent Liabilities | |||||||
| Other undisclosed noncurrent liabilities | |||||||
| Total noncurrent liabilities: | |||||||
| Total liabilities: | 108 | 0 | 15 | 15 | |||
| Equity | |||||||
| Equity, attributable to parent, including: | 19 | 38 | 104 | 235 | |||
| Common stock | 4 | 4 | 4 | 4 | |||
| Additional paid in capital | 360 | 360 | 360 | 360 | |||
| Accumulated deficit | (345) | (326) | (261) | (130) | |||
| Other undisclosed equity, attributable to parent | (0) | ||||||
| Total equity: | 19 | 38 | 104 | 235 | |||
| TOTAL LIABILITIES AND EQUITY: | 128 | 38 | 119 | 250 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Revenues | 102 | 35 | 15 | 43 | ||
| Gross profit: | 102 | 35 | 15 | 43 | ||
| Operating expenses | (121) | (101) | (146) | (152) | ||
| Operating loss: | (19) | (66) | (131) | (109) | ||
| Nonoperating expense | (0) | |||||
| Interest and debt expense | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (19) | (66) | (131) | (109) | ||
| Other undisclosed income from continuing operations before income taxes | 0 | 0 | ||||
| Loss from continuing operations before income taxes: | (19) | (66) | (131) | (109) | ||
| Income tax expense | ||||||
| Loss from continuing operations: | (19) | (66) | (131) | (109) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (66) | (131) | (109) | |
| Net loss: | (19) | (66) | (131) | (109) | ||
| Other undisclosed net income attributable to parent | 0 | |||||
| Net loss available to common stockholders, diluted: | (19) | (66) | (131) | (109) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Net loss: | (19) | (66) | (131) | (109) | ||
| Other comprehensive loss | (131) | (109) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (19) | (66) | (262) | (218) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.